Jeffrey Scott Riley insider trades

Open-market stock purchases and sales by Jeffrey Scott Riley, Director at Gain Therapeutics, Inc, from SEC Form 4 filings since Dec 2, 2010.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -67%.

Recent trades

DateStockTradeValue
Jul 15, 2026GANX Gain Therapeutics, IncBought (not open market)—

Companies traded

  • GANX Gain Therapeutics, Inc: 1 buy, last Jul 15, 2026
  • SYN Synthetic Biologics, Inc: 5 buys, last Nov 30, 2016
  • AEN Adeona Pharmaceuticals, Inc: other filings, last Feb 3, 2012

Get free alerts when Jeffrey Scott Riley files a new trade →